CorMedix agrees to acquire substantially all Heron assets for $145 million cash plus stock

• CorMedix will acquire substantially all Heron Therapeutics assets for $145 million in cash, subject to adjustments, and 14,583,333 common shares.
• Heron could receive up to $55 million in ZYNRELEF-linked earn-outs, plus royalties on certain product sales.
• The acquisition adds four commercial-stage products used in institutional care, with estimated 2027 revenue of $125 million to $150 million.
• The deal is expected to immediately boost earnings and free cash flow, delivering $45 million to $60 million in annualized operating synergies.
• Closing is expected in the first quarter of 2027, subject to Heron shareholder approval, regulatory clearance and customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-117213), on November 09, 2026, and is solely responsible for the information contained therein.